We propose for the first time that E-cadherin destabilization accounts for HDGC pathogenicity, and that in the absence of clear clinical observations, in silico predictions should be used as a first approach to distinguish pathogenic from probably tolerated E-cadherin variants associated to HDGC or EODGC. This evidence concerns the gene DSG2 and Familial gastric cancer.